22 January 2020 - New Gonal-f 150 IU pen provides additional flexibility and convenience at every stage of the patients’ stimulation cycle.
Merck, a leading science and technology company, today announced that the European Commission has granted marketing authorisation for its new Gonal-f (follitropin alfa) 150 IU pen.
This means Merck now offers an even more comprehensive range of best-in-class pens, supporting patients from the beginning to the end of their fertility stimulation cycle, when lower doses are required.